1. Belenkov Yu.N., Mareev V.Yu. Treatment of heart failure in the 21st century: achievements, problems and lessons of medicine. Kardiologiia 2008; (2): 6–16. Russian (Беленков Ю.Н., Мареев В.Ю. Лечение сердечной недостаточности в 21 веке: достижения, вопросы и уроки доказательной медицины. Кардиология 2008; (2): 6–16).
2. Camm A.J. Atrial fibrillation and risk. Clin Cardiol 2012, 35 Suppl 1:1–2.
3. Guidelines for the management of atrial fibrillation. The Task Forse for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369–2429.
4. Zi D, Karen S, Leung T.K, Nattel S.Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100:87–95.
5. Tarzimanova A.I., Fomina I.G.The role of inflammation in the pathogenesis of atrial fibrillation. Kardiovaskulyarnaya Terapiya i Profilaktika 2006; 5(7):91–93. Russian (Тарзиманова А.И., Фомина И.Г. Роль воспаления в патогенезе фибрилляции предсердий. Кардиоваскулярная Терапия и Профилактика 2006; 5(7):91–93).
6. Kumagai K, Nakashima H, Sakn K. The HMG-COA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in canine sterile pericarditis model. Cardiovasc Res 2004; 62:105– 11.
7. Engelmann MDM, Svedsen J.H. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:2083–92.
8. Price D.T., Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107:85–97.
9. Oliveira G.H. Novel serologic markers of cardiovascular risk. Curr Atheroscler Rep 2005; 7;148–54.
10. Zakirova N.E., Oganov R.G., Zakirova A.N. Endothelial dysfunction in coronary artery disease. Rational Pharmacother Card 2008; 4:23–27. Russian (Закирова Н.Э., Оганов Р.Г., Закирова А.Н. Дисфункция эндотелия при ишемической болезни сердца. РФК 2008; 4:23–27).
11. Martynyuk T.V., Nakonechnikov S.N., Masenko V.P., Chazova I.E. Inhaled nitric oxide: clinical effects and influence on the profile of inflammatory markers in patients with idiopathic pulmonary hypertension. Rational Pharmacother Card 2012; 8(4):500–508. Russian (Мартынюк Т.В., Наконечников С.Н., Масенко В.П., Чазова И.Е. Ингаляционный оксид азота: клинические эффекты и влияние на профиль провоспалительных маркеров у пациентов с идиопатической легочной гипертензией. РФК 2012; 8(4):500–508.
12. Tzoulaki F. C-reactive protein, interleukin-6 and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population. Edinburgh artery study. Circulation 2005; 112:976– 983.
13. Zakirova A.N., Abdyukova E.R. Influence of β-blockers on cardiac remodeling and adhesive endothelial function in patients with coronary heart disease complicated with chronic heart failure and atrial fibrillation. Kardiologiia 2010; 3:11–15. Russian (Закирова А.Н., Абдюкова Э.Р. Влияние β-адреноблокаторов на ремоделирование миокарда и адгезивную функцию эндотелия у больных ишемической болезнью сердца, осложненной хронической сердечной недостаточностью и фибрилляцией предсердий. Кардиология 2010; 3:11–15).
14. ACC/AHA/ASE 2003 Guidelines Update to the Clinical Application of Echocardiography. Circulation 2003; 108(9):1146–62.
15. Gronefeld G.C., Hohnloser S.H. Heart failure complicated by atrial fibrillation: mechanistic, prognostic and therapeutic implications. J Cardiovasc Pharmacol Ther 2003; 8(2): 107–13.
16. Klein G, Szalay Z. Structural correlate of atrial fibrillation in human patients. Cardiovasc Rec 2002; 54(2): 361–79.
17. Hansson G.K. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352(16): 1685–1695.
18. Lutay M.I., Golikova I.P., Deak S.I. Systemic inflammation in patients with coronary heart disease Ukrainskiy meditsinskiy zhurnal 2006; 2:80–83. Ukrainian (Лутай М.И., Голикова И.П., Деaк С.И. Системное воспаление у пациентов с ишемической болезнью сердца: Украинский медицинский журнал 2006; 2:80–83).
19. Marui N, Offermann M.K., Swerlick R. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression age regulated through an antioxidant – sensive mechanism in human valcular endothelial cells. J Clin Invest 1993; 92:1866–74.
20. Hwang S.J., Ballantyne C.B., Sharrett A.R. Circulating adhesion molecules VCAM-1, JCAM-1, and Eselectin in carotid atherosclerosis and incident coronary heart disease cases: the Aterosclerosis Risk In Communities (ARIC) Study. Circulation 1997; 96:4219–25.
21. Hasper D., Hummel M, Kleber E. Systemic inflammation in palients with heart failure. Eur Heart J 1998; 19:761–765.
22. Dernellis J., Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25:1100–107.
23. Nattel S. New ideas about atrial fibrillation 50 yearz on. Nature 2002; 415: 219–26.
